This content is for members only
This content is for members only
As you may have read recently or noticed, shares of BioXcel Therapeutics (NASDAQ:BTAI) recorded a 627% gain in seven months after SanaCurrents’ December 20, 2019 report that forecast positive outcomes for two, separate phase III trials for BioXcel’s drug BXCL501. The 627% […]
This content is for members only
This content is for members only
This content is for members only
This content is for members only
After the market closed on June 11, Selecta Biosciences, Inc. (NASDAQ:SELB) announced it had entered a licensing deal with $SOBI (STO:SOBI), granting most of the global rights to Selecta’s phase III gout drug, SEL-212, to SOBI. Selecta’s stock fell about […]